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Abstract
Rare diseases affect less than 1 in 2000 or 5 in 10,000 people by definition. Most 
of those diseases have genetic basis (80% of cases) and first symptoms appear in 
early childhood (50% of cases). Most of these diseases are chronic and degenerative 
and pharmacotherapy is not available for many of them. Until today, there are more 
than 7000 rare diseases. In Serbia, the problem of diagnosis and pharmacotherapy 
of rare diseases is currently under public scrutiny. Patients who suffer from rare 
diseases in Serbia face many challenges in terms of awareness, timely diagnosis, and 
adequate treatment. These people are often misdiagnosed or the diagnosis is delayed 
due to several problems: lack of awareness among medical professionals, lack of 
expertise, unavailability and/or high costs of diagnostic tests, etc. According to the 
National Organization of Patients with Rare Diseases in Serbia (NORBS), many 
diagnostic procedures have to be conducted abroad and the process comprises many 
difficulties: high costs, travel expenses, or transportation of biological material. 
Although national legislation ensures the availability of drugs for those diseases, 
pharmacotherapy is faced with many problems. In this work, we aim to show that 
improvement of the knowledge regarding rare diseases among both professionals 
and patients represents a crucial step for enhancement of perspectives for those 
patients in our community.
Keywords: rare diseases, pharmacotherapy, physicians, patients, knowledge, 
attitudes
1. Introduction
A rare disease or an orphan disease represents any disease that affects a small 
percentage of the population. According to data from Europe, a disease or disorder 
is defined as rare when it affects less than 1 in 2000 citizens (there are so rare 
diseases that affect 1 person in 100,000 or even less) [1].
The most significant matters concerning rare diseases (RDs) are as follows: (1) 
these diseases are often chronic, progressive, degenerative, and life-threatening; 
(2) most of them (80%) have identified genetic base; (3) in the majority of 
cases (75%), the first symptoms appear in early childhood (30% of rare disease 
patients die before the age of 5); (4) RDs represent disabling conditions: they have 
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tremendous social and socio-economic impact on one country, because they affect 
not only the patients but also their families and the whole society.
It is estimated that more than 7000 rare diseases have been detected and described 
so far. European Organization for Rare Diseases (EURORDIS) represents a unique, 
non-profit alliance of rare disease patient organizations from 72 European countries. 
According to this organization, 30 million people in Europe suffer from some of the 
numerous rare diseases. A similar organization exists in Serbia (NORBS), which 
estimates that such patients are about half a million in our community [2].
Patients suffering from RDs are faced with numerous complications: deficit 
of public and scientific education of the diseases, delay in diagnosis (or lack of 
access to correct diagnosis), heavy social consequences (stigmatization, isolation, 
discrimination, reducing professional opportunities, etc.), lack of appropriate 
quality healthcare, high prices of these drugs and complicated procedures for their 
procurement, etc. [3]. Also, people affected with RDs may require other medicinal 
devices (diapers, special nutritional preparations, wheelchairs, etc.). The fact that 
these expenses are not reimbursed by the national health insurance represents 
additional problem in everyday life of these patients and their family. All these 
obstacles have led to many charitable actions aimed at collecting donations in order 
to improve treatment solutions as well as to involve media in raising public aware-
ness of this topic [2, 3].
Although national legislation ensures the availability of drugs for those diseases, 
(“orphan drugs”), the National Register of RDs still does not exist in Serbia. It is 
important to know that there are hospital registries for some rare diseases but a sys-
temic and universal approach is still missing. Additionally, most of these conditions 
are not coded in the ICD-10, which only has codes for 500 of the rare diseases [4].
Beside this, pharmacotherapy of rare diseases in our country is also challenged 
with many difficulties, not just due to legislative obstacles. Although there are not 
enough registered orphan drugs, many of them can be found on the “black” market, 
in private pharmacies at very high prices and without adequate supervision [5].
Serbia has made certain progress in the area, but numerous unresolved issues 
remain. It should be point out that the importance of this topic was recognized 
in our country for the first time few years ago, in 2014. At that moment, certain 
amendments displayed the need for the development of centers for rare diseases 
and also declared this group of patients as a special category with the right to use 
free health insurance. In addition, a special budget from the Ministry of Health was 
assigned to finance treatment with orphan drugs [6, 7].
In addition to the above, National Organization for Rare Diseases in Serbia 
(NORBS) represents a non-governmental, non-profit organization that was 
founded in 2010 with an aim to improve the quality of life for people affected with 
RDs in Serbia.
2.  Rare diseases patients as vulnerable subjects in clinical trials: 
bioethical challenges
The particular question that arises here is related to bioethical aspects of phar-
macotherapy of these diseases and all obstacles along the way of examination of 
special kind of drugs intended to treat small number of patients (the so-called 
orphan drugs).
The issue of ethical and bioethical aspects of experiments including humans 
(which was the forerunner of clinical trials) was almost completely ignored by 
medical ethics of the late nineteenth and early twentieth century. It is relevant 
to mention that the sensitivity toward medical research subjects belonging to 
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vulnerable groups was first expressed clearly in the Declaration of Helsinki (it was 
adopted by the 18th World Medical Association General Assembly in Helsinki in 
1964, and revised several times (most recently in 2013) [8].
Generally, patients suffering from rare diseases could be considered as the 
members of vulnerable groups. As we already mentioned, most of these condi-
tions are chronic, degenerative, and life-threatening, of unknown or genetic 
origin, and mainly affect children [2, 3]. Some of these diseases have a devastat-
ing impact on all aspects of the patients’ lives and their careers. Additionally, the 
development and availability of drugs for RDs could challenge basic bioethical 
principles. Four commonly accepted principles of health care ethics, excerpted 
from Beauchamp and Childress, include the: (1) principle of respect for autonomy, 
(2) principle of non-maleficence, (3) principle of beneficence, and (4) principle 
of justice [9].
The first bioethical principle—respect for the autonomy of the patient—means 
that the patient has the capacity to act intentionally, with understanding, and with-
out controlling influences that would mitigate against a free and voluntary act. This 
principle is the basis for the practice of “informed consent” in the physician/patient 
transaction regarding health care, which represents one of postulates of modern 
clinical trial. The principle of non-maleficence requires us, as medical profession-
als, to not intentionally create harm or injury to the patient, either through acts of 
commission or omission. The meaning of the Principle of Beneficence is that health 
care providers have a duty to be of benefit to the patient, as well as to take positive 
steps to prevent and to remove harm from the patient. Finally, justice in health care 
is usually defined as a form of fairness, or as Aristotle once said, “giving to each that 
which is his due.” [9].
In addition to the above, the utilitarian concept of bioethics could not be fully 
applied in this matter since it favors development of drugs for common disorders 
instead of the rare ones. One could argue that diseases are rare but there are a lot of 
patients suffering from them [5, 6]. These diseases represent a challenge not only 
for the individual and the family of the patient but also for the medical profession-
als, the entire health care system, and the complete society.
By considering the patients suffering from rare diseases as the members of 
vulnerable groups, we want to stress the presence of individualized medicine trend 
in contemporary medicine. Ethical declarations, codices, bioethical documents, 
and the function of the ethical committees were the indicators of individualizing 
medicine trend. Regarding the rare diseases issue, the indicators of individualizing 
medicine trend are certain documents: (1) EU Regulation on Orphan Medicinal 
Products (1999); (2) EU Regulation on Pediatric Drugs (2006); (3) Programme 
of Community Action in the Field of Public Health (2007–2013); and (4) EU 7th 
Framework Programme for Research (2007–2013) [8].
It can be concluded that above-mentioned case of “moving” from a random 
sample of hospitalized patients to specific group of patients, members of vulner-
able groups, is the indicator of individualizing medicine trend and it continues to 
develop. One of its goals is certainly, we consider, the rare disease issue and the 
specific patient-physician encounter that includes the rare disease patient, namely, 
the patient sui generis as the subject of specific therapeutic research [8].
3. The aim of our study
Our research group deals with different aspects of rare diseases in our commu-
nity: pharmacotherapy, bioethical issues, social significance, importance of educa-
tion among medical students, patients, and professionals, etc.
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In the first part of this work, we will briefly present the main results of the pilot 
study regarding pharmacotherapy of rare diseases conducted among physicians and 
clinical pharmacists who deal with these kinds of patients in Serbia.
In the next part of examination, we will present the main results of the survey 
conducted among patients suffering from rare diseases in our country.
4.  The knowledge and attitudes of physicians and clinical pharmacists 
regarding pharmacotherapy of rare diseases in Serbia: a pilot study
In Serbia, clinical trials in the field of rare diseases are extremely rare and mainly 
relate to rare oncological diseases.
We considered that it would be important to examine the attitudes and knowl-
edge of physicians and clinical pharmacists regarding the pharmacotherapy of rare 
diseases in Serbia. An anonymous pilot survey entitled “Attitudes of Physicians and 
Pharmacists Regarding Pharmacotherapy of rare diseases in Serbia” was designed 
and conducted by employees of the Department of Pharmacology, Clinical 
Pharmacology and Toxicology in a selected sample of subjects (N = 11, Internal 
Medicine Clinic and Central Pharmacy, KBC “Bezanijska Kosa” in Belgrade).  
The survey consisted of both open- and closed-ended questions. The attitudes of 
medical professionals were assessed by the 10-point Likert scale. The total response 
rate was 97.2%.
4.1  Physicians’ and pharmacists’ knowledge and attitudes concerning rare 
diseases: results
Our respondents found that the greatest problems of patients suffering from 
rare diseases in our environment are: lack of scientific knowledge (23%), com-
plicated procedures for the procurement of drugs (21%), the lack of a sufficient 
number of registered medicines for these diseases (14%), etc. Although our exam-
inees considered this issue as highly important in our country (on a scale of 0–10, 
our respondents gave an average score of 9), the majority of them (64%) assessed 
they were not sufficiently familiar with the existing legislation. According to our 
respondents, the treatment of patients with rare diseases in our environment can 
be improved: by forming a National Strategy for RDs (23%), raising general and 
professional awareness (20%), by creating a register of patients with rare diseases 
(20%), etc.
5.  The knowledge and attitudes of patients suffering from rare diseases 
in Serbia
In the next part of our investigation, we performed a cross-sectional study 
for 5 weeks on outpatients and inpatients (Neurology Clinic, Department for 
Neuromuscular Disorders, Clinical Center of Serbia) who suffered from rare 
neurological diseases.
The anonymous questionnaire concerning the knowledge and attitudes of rare 
diseases and its pharmacotherapy was completed by a total of 60 patients (39 were 
male and 21 were female). The questionnaire consisted of both open- and closed-
ended questions, and patients’ attitudes were assessed by the 10-point Likert scale.
All of our respondents suffered from different neurological diseases (myasthe-
nia gravis, myotonic dystrophy, polyneuropathy, multiple sclerosis, syringomyelia, 
amyotrophic lateral sclerosis, etc.). The total response rate was 95.83%.
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5.1 Patients’ knowledge and attitudes concerning rare diseases: results
This part of our survey showed that slightly more than a third of participants 
knew the exact prevalence and definition of rare diseases in Europe. Although more 
than 70% of patients answered they knew what kind of disease is defined as “rare,” 
only half of the participants believed that they suffered from rare disease.
Our respondents found that dealing with this issue in our community is very 
important (median value: 9; interquartile range: 8–10), while availability of “orphan 
drugs” is still poor (median value: 2; interquartile range: 1–6).
The most important problems faced by patients suffering from rare diseases in 
Serbia include: lack of public and scientific knowledge (21.83% and 14.78%), insuf-
ficient number and cost of orphan drugs (14.08%), legislative obstacles (12.67%), 
delay in diagnosis and misdiagnosis (12.67%), etc.
It should be pointed out that only 16.6% of examined patients were part of some 
rare diseases patients’ organizations and just a quarter of our respondents (26.6%) 
agreed to participate in clinical trials concerning orphan drugs.
According to our participants, the availability of drugs for RDs could be 
enhanced by the efforts of: the state (55%), medical doctors (30%), pharmaceutical 
companies and pharmacies (10%), rare diseases patients’ organizations (3.33%), etc.
Finally, in order to improve the pharmacotherapy of RDs in our country, the 
examined participants suggested the following: well-timed diagnostics (25.78%), 
progress of the general awareness regarding this topic (22.64%), clarified orphan 
drug approval processes (16.9%), registration of more RDs drugs (11.3%), creating 
a RDs patients’ register (7.6%), forming a National Strategy for RDs (6.2%), full 
implementation of legislation (4.7%), adequate control of orphan drugs available in 
private pharmacies in Serbia (4.25%), etc.
6. Discussion
In general, our questionnaires showed that the examined physicians and clinical 
pharmacists, as well as patients, were very interested in expressing their attitudes 
regarding the issue of rare diseases and their treatment in our country. This is 
confirmed by the high percentage of provided answers (the total response rate was 
97.2% and 95.83%, respectively).
The first thing to notice here is that both the patients and medical professionals 
did not show sufficient knowledge regarding this topic. It is important to emphasize 
that both groups of our participants were directly involved in this issue (for survey, 
medical professionals who were in daily practice in contact with RDs patients and 
patients who belonged to the RDs patients’ group by definition were selected).
Our respondents estimated the importance of rare diseases in our society as a 
problem of crucial importance. Here, we noticed a significant difference in attitudes 
between RDs patients and third- and sixth-year medical students that we have 
examined in previous research (P < 0.01). In opposite, the observed patients and 
examined students showed a similar opinion regarding the overall quality of health 
care of RDs patients, rated it as insufficient (P < 0.05) [10].
We need to reveal that the issue of pharmacotherapy of rare diseases involves 
different kind of ethical dilemmas and controversies. That is why we strongly 
believe that understanding and analyzing such a sensitive topic must also imple-
ment knowledge of basic principles of biomedical ethics [11–14].
In our survey, respondents found that the state was most responsible for the 
improvement of availability of orphan drugs. However, we need to be aware that 
national policies and activities of the state start from the initiative of those who 
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participate in the health system of one country (policy-makers, members of the regu-
latory bodies, medical doctors, pharmacists, patients, etc.). Our research has shown 
that patients do not participate sufficiently in these activities and do not take an active 
role in the fight to improve their position in society. Related to these findings, Baker 
and Trisnadi in their works emphasized the importance of understanding personal 
responsibility to address a bioethically vulnerable issue in one community [15, 16].
In the last three decades, the concept of “medicalization” of society (“a pill for 
every ill”) has been increasingly present in numerous bioethical debates [17]. In 
contrast to this phenomenon, there is a real need to develop novel drugs for rare 
diseases and their inaccessibility in many societies, on the one hand, and the lack of 
concern of the pharmaceutical industry regarding this topic, on the other [18, 19].
A controversial and substantive question would be is it reasonably and ethically 
justified to invest large amounts of money to treat a small number of patients? In a 
previous study performed on third- and sixth-year medical students, we received 
an affirmative answer to this question in both groups (P < 0.05) [10].
The most important results of survey conducted among third- and sixth-year 
medical students are shown in Table 1.
Finally, in order to improve the pharmacotherapy of rare diseases in Serbia, 
medical professionals and patients similarly suggested: improvement of general and 
scientific knowledge, well-timed diagnostics, simplified procedures for drug provi-
sion, registration of more appropriate drugs, etc. (see Tables 2 and 3).
The first comprehensive study was recently published by Joldic et al. related 
to the needs of patients with rare diseases in Serbia. According to this paper, four 
different groups of needs are identified: needs for health care, needs for social 
care, psychological needs, and other needs. The most important problems of 
RDs patients and their families arise first from the insufficient information and 
knowledge on this topic and second from the non-recognition of rare diseases in the 
legislation of health care system [7, 20–24].
The most important problems of patients (%) Third year Sixth year P value
Lack of information in general public 67.71 56.61 <0.01
Lack of scientific knowledge 31.42 37.19 >0.05
Lack of access to correct diagnosis 46.28 42.56 >0.05
Lack of appropriate quality health care 49.71 40.08 <0.05
Lack of a sufficient number of registered drugs 41.43 70.24 <0.0001
Complicated procedures of drug provision 60.00 63. 22 >0.05
High prices of drugs 86.29 80.58 >0.05
Other causes 2.00 1.65 >0.05
How to improve pharmacotherapy of rare diseases (%)
Raise general awareness and expertise 30.57 60.00 <0.0001
Well-timed diagnostics 44.86 63.22 <0.0001
Simplified procedures for drug provision 50.00 70.66 <0.0001
Registration of more appropriate drugs 55.43 69.01 <0.01
The establishment of the National Plan for Rare 
Diseases
64.57 74.38 <0.05
Create the registry of rare diseases 54.58 53.72 >0.05
Bold values are represented statistically significant difference between groups.
Table 1. 
Medical students’ knowledge and attitudes concerning rare diseases.
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7. Conclusions
We can conclude that our participants showed will to express their atti-
tudes regarding this important medical, societal, and bioethical concern in our 
The most important problems of patients (%)
1. Lack of scientific knowledge 23
2. Complicated procedures for the procurement of drugs 21
3. Lack of a sufficient number of registered drugs for these diseases 14
4. Lack of access to correct diagnosis 12
5. Complicated procedures of drug provision 11
6. High prices of drugs 11
7. Other 8
How to improve pharmacotherapy of rare diseases (%)
1. The establishment of the National Strategy for Rare Diseases 23
2. Raise general and professional awareness 20
3. Create registries of rare diseases 20
4. Well-timed diagnostics 18
5. Registration of more appropriate drugs 13
6. Other 6
Table 2. 
Physicians’ and pharmacists’ knowledge and attitudes concerning rare diseases.
The most important problems of patients %
1. Lack of public knowledge 21.83
2. Lack of scientific knowledge 14.78
3. Lack of a sufficient number of registered drugs 14.08
4. Lack of access to correct diagnosis 12.67
5. Complicated procedures of drug provision 11.75
6. High prices of drugs 11.30
7. Unavailability of these drugs in private pharmacies 8.40
8. Other 5.19
How to improve pharmacotherapy of rare diseases %
1. Well-timed diagnostics 25.78
2. Raise general awareness 22.64
3. Simplified procedures for drug provision 16.90
4. Registration of more appropriate drugs 11.30
5. Create registries of rare diseases 7.60
6. The establishment of the National Strategy for Rare Diseases 6.20
7. Full implementation of legislation 4.7
8. Other 4.88
Table 3. 
The knowledge and attitudes of patients suffering from rare diseases
Rare Diseases
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community. Patients, as well as medical doctors and pharmacists, are aware of the 
most significant challenges concerning this topic in Serbia.
However, we need to improve both knowledge and attitudes of all participants 
in the health care system. Patients should be encouraged to more actively advocate 
for their rights through the formation of associations, and medical professionals to 
make greater efforts in the field of education on this subject.
Additionally, we believe that education is very important among medical 
students as future physicians, as our previous research has proven.
Finally, we would like to point out that at this moment our country has already 
conducted different kind of activities in order to create national strategy and regis-
tries of RDs, to form centers of expertise, to improve accessibility of orphan drugs, 
etc. Concerning this, we consider this is the critical point for conducting public 
discussion regarding this issue. An initiative like this should involve not just medical 
professionals and regulatory bodies, but the RDs patients and the general public as 
well. We strongly believe this is the unique way to significantly improve the position 
of these patients in our community in future.
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